Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs

Journal of Surgical Oncology

Volumn 106, Issue 4, 2012, Pages 441-447

  Miyata, Hiroshi ^a   Yamasaki, Makoto ^a   Kurokawa, Yukinori ^a   Takiguchi, Shuji ^a   Nakajima, Kiyokazu ^a   Fujiwara, Yoshiyuki ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

adjacent organ; chemoradiotherapy; chemotherapy; esophageal cancer; T4

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER SURGERY; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; ESOPHAGUS CANCER; ESOPHAGUS PERFORATION; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES;

EID: 84865144445     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23081     Document Type: Article

References (40)

1. Muller JM, Erasmi H, Stelzner M, et al.: Surgical therapy of oesophageal carcinoma. Br J Surg 1990; 77: 845-857. (Pubitemid 20249685)
2. Lerut T, Nafteux P, Moons J, et al.: Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: Impact on staging, disease-free survival, and outcome: A plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240: 962-972.
3. Ikeda K, Ishida K, Sato N, et al.: Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus 2001; 14: 197-201. (Pubitemid 34170808)
4. Fujita H, Sueyoshi S, Tanaka T, et al.: Esophagectomy: Is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg 2005; 29: 25-30. (Pubitemid 40576484)
5. Matsubara T, Ueda M, Kokudo N, et al.: Role of esophagectomy in treatment of esophageal carcinoma with clinical evidence of adjacent organ invasion. World J Surg 2001; 25: 279-284. (Pubitemid 32410365)
6. Noguchi T, Moriyama H, Wada S, et al.: Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma. Dis Esophagus 2003; 16: 94-98. (Pubitemid 36992380)
7. Ancona E, Ruol A, Castoro C, et al.: First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: Final report on 163 consecutive patients with 5-year follow-up. Ann Surg 1997; 226: 714-723.
8. Tachibana M, Dhar DK, Kinugasa S, et al.: Surgical treatment for locally advanced (T4) squamous cell carcinoma of the thoracic esophagus. Dysphagia 2002; 17: 255-261. (Pubitemid 36919816)
9. Kaneko K, Ito H, Konishi K, et al.: Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer 2003; 88: 18-24. (Pubitemid 36241212)
10. Crosby TD, Brewster AE, Borley A, et al.: Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 2004; 90: 70-75. (Pubitemid 38174941)
11. Itoh Y, Fuwa N, Matsumoto A, et al.: Outcomes of radiotherapy for inoperable locally advanced (T4) esophageal cancer-retrospective analysis. Radiat Med 2001; 19: 231-235. (Pubitemid 33111366)
12. Nishimura Y, Suzuki M, Nakamatsu K, et al.: Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 2002; 53: 134-139. (Pubitemid 34465816)
13. Ohtsu A, Boku N, Muro K, et al.: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915-2921. (Pubitemid 29415253)
14. Takagawa R, Kunisaki C, Makino H, et al.: Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus. Dis Esophagus 2009; 22: 482-489.
15. Ishida K, Ando N, Yamamoto S, et al.: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 2004; 34: 615-619. (Pubitemid 40662717)
16. Sasamoto R, Sakai K, Inakoshi H, et al.: Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP). Int J Clin Oncol 2007; 12: 25-30. (Pubitemid 46472549)
17. Van Raemdonck D, Van Cutsem E, Menten J, et al.: Induction therapy for clinical T4 oesophageal carcinoma; A plea for continued surgical exploration. Eur J Cardiothorac Surg 1997; 11: 828-837. (Pubitemid 27261880)
18. Malaisrie SC, Untch B, Aranha GV, et al.: Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: Experience at a single institution. Arch Surg 2004; 139: 532-538.
19. de Manzoni G, Pedrazzani C, Pasini F, et al.: Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol 2007; 95: 261-266.
20. Yano M, Shiozaki H, Tsujinaka T, et al.: Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy. J Am Coll Surg 2000; 191: 626-634. (Pubitemid 32004988)
21. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
22. Osaka Y, Shinohara M, Hoshino S, et al.: Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res 2011; 31: 633-638.
23. Sobin LH, Wittekind C:, TNM classification of alignant tumours, 6th edition. New York: Wiley; 2002.
24. Halvorsen RA, Jr., Thompson WM:, CT of esophageal neoplasms. Radiol Clin North Am 1989; 27: 667-685. (Pubitemid 19150185)
25. Ogawa Y, Nishiyama K, Ikesoe J, et al.: Preoperative assessment of tumor invasion of the intrathoracic esophageal carcinoma. In:, Siewert JR, Holscher AH, editors. Disease of the esophagus. Berlin, Germany: Springer-Verlag; 1987. pp. 203-206.
26. Miyata H, Yamasaki M, Takiguchi S, et al.: Prognostic value of endoscopic biopsy findings after induction chemoradiotherapy with and without surgery for esophageal cancer. Ann Surg 2010; 253: 279-284.
27. Miyata H, Yoshioka A, Yamasaki M, et al.: Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer 2009; 115: 3324-3334.
28. Japan Esophageal Society: Japanese classification of esophageal cancer, tenth edition. Esophagus 2009; 6: 1-25.
29. Roussel A, Cheze S, Jacob JH, et al.: Radiation therapy in esophageal carcinoma with broncho-tracheal involvement (BTI): The center francois baclesse (CFB) experience. Proc Am Soc Clin Oncol 1995; 14: 190a, abstr. 438.
30. Mandard AM, Dalibard F, Mandard JC, et al.: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 1994; 73: 2680-2686. (Pubitemid 24166250)
31. Chang F, Deere H, Mahadeva U, et al.: Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy; Practical guidelines and current issues. Am J Clin Pathol 2008; 129: 252-262. (Pubitemid 352029316)
32. Berger AC, Farma J, Scott WJ, et al.: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4336.
33. Schneider PM, Baldus SE, Metzger R, et al.: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer. Implication for response classification. Ann Surg 2005; 5: 684-692. (Pubitemid 41567124)
34. Brücher BL, Becker K, Lordick F, et al.: The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006; 106: 2119-2127. (Pubitemid 43673232)
35. Rizk NP, Venkatraman E, Bains MS, et al.: American joint committee on cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25: 507-512. (Pubitemid 350002956)
36. Becker K, Mueller JD, Schulmacher C, et al.: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-1530. (Pubitemid 37151509)
37. Stahl M, Stuschke M, Lehmann N, et al.: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317. (Pubitemid 46218723)
38. Bedenne L, Michel P, Bouché O, et al.: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168. (Pubitemid 46640561)
39. Heath EI, Burtness BA, Heitmiller RF, et al.: Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000; 18: 868-876. (Pubitemid 30106619)
40. Ajani JA, Komaki R, Putnam JB, et al.: A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001; 92: 279-286. (Pubitemid 32664433)